IFIT3 and systemic sclerosis: Therefore, we hypothesise that intervening in the IFIT3‐mediated phosphorylation of TBK1 (pTBK1) may inhibit the activation of pDCs, reduce IFN‐I production, and thereby alleviate the onset and progression of SSc.